IDH1 and acute myeloid leukemia: Isavuconazole has also been suggested as an alternative antifungal option for patients with AML on IDH1/2 inhibitors, such as ivosidenib, as the other azole antifungals and IDH1/2 inhibitors prolong the QTc interval, while isavuconazole has no QTc prolongation effects.105